Failing to plan and planning to fail. Can we predict the future growth of demand on UK Eye Care Services?

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.


  1. 1.

    Bunce C, Wormald R. Causes of blind certifications in England and Wales: April 1999-March 2000. Eye. 2008;22:905–11.

  2. 2.

    Rutherford T. Population ageing: statistics; wwwparliamentuk/briefing-papers/sn03228pdf, 2012; SN/SG/3228.

  3. 3.

    Bastawrous A, Hennig BD. The global inverse care law: a distorted map of blindness. Br J Ophthalmol. 2012;96:1357–8.

  4. 4.

    Buchan JC, Amoaku W, Barnes B, Cassels-Brown A, Chang BY, Harcourt J, et al. How to defuse a demographic time bomb: the way forward? Eye. 2017;31:1519–22.

  5. 5.

    Wong WL, Su X, Li X, Cheung CM, Klein R, Cheng CY, et al. Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis. Lancet Glob Health. 2014;2:e106–16.

  6. 6.

    Rudnicka AR, Mt-Isa S, Owen CG, Cook DG, Ashby D. Variations in primary open-angle glaucoma prevalence by age, gender, and race: a Bayesian meta-analysis. Invest Ophthalmol & Vis Sci. 2006;47:4254–61.

  7. 7.

    Coleman D. Projections of the Ethnic Minority populations of the United Kingdom 2006–2056. Popul Dev Rev. 2010;36:441–86.

  8. 8.

    Rees P, Wohland P, Norman P, Boden P. Ethnic population projections for the UK, 2001–2051. J Popul Res. 2012;29:45–89.

  9. 9.

    Rees PH, Wohland P, Norman P, Lomax N, Clark SD. Population projections by ethnicity: Challenges and a Solution for the United Kingdom. In: Swanson, DA, (ed.) The Frontiers of Applied Demography. Springer International Publishing, (New York City, USA) ISBN 978-3-319-43327-1. 2017. p. 383–408.

  10. 10.

    Rauf A, Malik R, Bunce C, Wormald R. The British Asian community eye study: outline of results on the prevalence of eye disease in British Asians with origins from the Indian subcontinent. Indian J Ophthalmol. 2013;61:53–8.

  11. 11.

    Leske MC, Connell AM, Schachat AP, Hyman L. The Barbados Eye Study. Prevalence of open angle glaucoma. Arch Ophthalmol (Chic, Ill: 1960). 1994;112:821–9.

  12. 12.

    Tielsch JM, Sommer A, Katz J, Royall RM, Quigley HA, Javitt J. Racial variations in the prevalence of primary open-angle glaucoma. The Baltimore Eye Survey. JAMA. 1991;266:369–74.

  13. 13.

    Ntim-Amponsah CT, Amoaku WM, Ofosu-Amaah S, Ewusi RK, Idirisuriya-Khair R, Nyatepe-Coo E, et al. Prevalence of glaucoma in an African population. Eye. 2004;18:491–7.

  14. 14.

    Reidy A, Minassian DC, Vafidis G, Joseph J, Farrow S, Wu J, et al. Prevalence of serious eye disease and visual impairment in a north London population: population based, cross sectional study. BMJ (Clin Res Ed). 1998;316:1643–6.

  15. 15.

    Evans JR, Fletcher AE, Wormald RP. Age-related macular degeneration causing visual impairment in people 75 years or older in Britain: an add-on study to the Medical Research Council Trial of Assessment and Management of Older People in the Community. Ophthalmology. 2004;111:513–7.

  16. 16.

    Augood CA, Vingerling JR, de Jong PT, Chakravarthy U, Seland J, Soubrane G, et al. Prevalence of age-related maculopathy in older Europeans: the European Eye Study (EUREYE). Arch Ophthalmol (Chic, Ill: 1960). 2006;124:529–35.

  17. 17.

    Friedman DS, Wolfs RC, O'Colmain BJ, Klein BE, Taylor HR, West S, et al. Prevalence of open-angle glaucoma among adults in the United States. Arch Ophthalmol (Chic, Ill: 1960). 2004;122:532–8.

  18. 18.

    Frost A, Hopper C, Frankel S, Peters TJ, Durant J, Sparrow J. The population requirement for cataract extraction: a cross-sectional study. Eye. 2001;15(Pt 6):745–52.

  19. 19.

    McCarty CA, Mukesh BN, Fu CL, Taylor HR. The epidemiology of cataract in Australia. Am J Ophthalmol. 1999;128:446–65.

  20. 20.

    Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care. 2004;27:1047–53.

  21. 21.

    Shaw JE, Sicree RA, Zimmet PZ. Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res Clin Pract. 2010;87:4–14.

  22. 22.

    Scanlon PH, Aldington SJ, Stratton IM. Epidemiological issues in diabetic retinopathy. Middle East Afr J Ophthalmol. 2013;20:293–300.

  23. 23.

    Amos AF, McCarty DJ, Zimmet P. The rising global burden of diabetes and its complications: estimates and projections to the year 2010. Diabet Med: a J Br Diabet Assoc. 1997;14(Suppl 5):S1–85.

  24. 24.

    King H, Aubert RE, Herman WH. Global burden of diabetes, 1995-2025: prevalence, numerical estimates, and projections. Diabetes Care. 1998;21:1414–31.

  25. 25.

    Minassian DC, Owens DR, Reidy A. Prevalence of diabetic macular oedema and related health and social care resource use in England. Br J Ophthalmol. 2012;96:345–9.

  26. 26.

    Gonzalez EL, Johansson S, Wallander MA, Rodriguez LA. Trends in the prevalence and incidence of diabetes in the UK: 1996-2005. J Epidemiol Community Health. 2009;63:332–6.

  27. 27.

    Huang ES, Basu A, O’Grady M, Capretta JC. Projecting the future diabetes population size and related costs for the U.S. Diabetes Care. 2009;32:2225–9.

  28. 28.

    Waldeyer R, Brinks R, Rathmann W, Giani G, Icks A. Projection of the burden of type 2 diabetes mellitus in Germany: a demographic modelling approach to estimate the direct medical excess costs from 2010 to 2040. Diabet Med: a J Br Diabet Assoc. 2013;30:999–1008.

  29. 29.

    Foot B, MacEwen C. Surveillance of sight loss due to delay in ophthalmic treatment or review: frequency, cause and outcome. Eye. 2017;31:771–5.

  30. 30.

    The National Patient Safety Agency (NPSA). Preventing delay to follow up for patients with glaucoma. NPSA/2009/RRR004, June 2009.

Download references

Author information

Correspondence to John Cameron Buchan.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Additional information

Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark